BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang L, Tai YT, Ho MZG, Qiu L, Anderson KC. Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era. Exp Hematol Oncol 2017;6:20. [PMID: 28725493 DOI: 10.1186/s40164-017-0081-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Karami Fath M, Babakhaniyan K, Anjomrooz M, Jalalifar M, Alizadeh SD, Pourghasem Z, Abbasi Oshagh P, Azargoonjahromi A, Almasi F, Manzoor HZ, Khalesi B, Pourzardosht N, Khalili S, Payandeh Z. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. Vaccines (Basel) 2022;10:1448. [PMID: 36146527 DOI: 10.3390/vaccines10091448] [Reference Citation Analysis]
2 Johnstone M, Vinaixa D, Turi M, Morelli E, Anderson KC, Gulla A. Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma. Cells 2022;11:2519. [PMID: 36010596 DOI: 10.3390/cells11162519] [Reference Citation Analysis]
3 Zhao M, Yin F. Hepatic epithelioid hemangioendothelioma: Clinical characteristics, diagnosis, treatment, and prognosis. World J Clin Cases 2022; 10(17): 5606-5619 [DOI: 10.12998/wjcc.v10.i17.5606] [Reference Citation Analysis]
4 Liu X, Zhang Z, Huang J, Tan H, Yang Z. Efficacy and Safety of Interferon-Alpha 2b for Patients with Hepatic Epithelioid Hemangioendothelioma: Outcomes of a Case-Series Analysis. Cancer Manag Res 2021;13:8273-9. [PMID: 34764690 DOI: 10.2147/CMAR.S334171] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Fan L, Xu G, Cao J, Li M, Zhang H, Li F, Qi X, Zhang X, Li Z, Han P, Yang X. Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC. Cancers (Basel) 2021;13:5574. [PMID: 34771735 DOI: 10.3390/cancers13215574] [Reference Citation Analysis]
6 Pauli G, Chao PH, Qin Z, Böttger R, Lee SE, Li SD. Liposomal Resiquimod for Enhanced Immunotherapy of Peritoneal Metastases of Colorectal Cancer. Pharmaceutics 2021;13:1696. [PMID: 34683992 DOI: 10.3390/pharmaceutics13101696] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov 2021;2:468-83. [PMID: 34568832 DOI: 10.1158/2643-3230.bcd-21-0047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
8 Apollonio B, Ioannou N, Papazoglou D, Ramsay AG. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Front Oncol 2021;11:626818. [PMID: 33842331 DOI: 10.3389/fonc.2021.626818] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
9 Mondlane ER, Abreu-Mendes P, Martins D, Cruz R, Mendes F. The role of immunotherapy in advanced renal cell carcinoma: Review. Int Braz J Urol 2021;47:1228-42. [PMID: 33650838 DOI: 10.1590/S1677-5538.IBJU.2020.0681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ishiguro K, Kitajima H, Niinuma T, Maruyama R, Nishiyama N, Ohtani H, Sudo G, Toyota M, Sasaki H, Yamamoto E, Kai M, Nakase H, Suzuki H. Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis. Cell Death Discov 2021;7:7. [PMID: 33436557 DOI: 10.1038/s41420-020-00400-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
11 Xu S, Tang L, Li X, Fan F, Liu Z. Immunotherapy for glioma: Current management and future application. Cancer Lett 2020;476:1-12. [PMID: 32044356 DOI: 10.1016/j.canlet.2020.02.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 125] [Article Influence: 11.5] [Reference Citation Analysis]
12 Gao S, Wang S, Song Y. Novel immunomodulatory drugs and neo-substrates. Biomark Res 2020;8:2. [PMID: 31938543 DOI: 10.1186/s40364-020-0182-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
13 Guo J, Xiao Y, Iyer R, Lu X, Lake M, Ladror U, Harlan J, Samanta T, Tomlinson M, Bukofzer G, Donawho C, Shoemaker A, Huang TH. Empowering therapeutic antibodies with IFN-α for cancer immunotherapy. PLoS One 2019;14:e0219829. [PMID: 31393905 DOI: 10.1371/journal.pone.0219829] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
14 Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy. J Hematol Oncol 2018;11:121. [PMID: 30249264 DOI: 10.1186/s13045-018-0653-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 66] [Article Influence: 14.5] [Reference Citation Analysis]
15 Ishiguro K, Kitajima H, Niinuma T, Ishida T, Maruyama R, Ikeda H, Hayashi T, Sasaki H, Wakasugi H, Nishiyama K, Shindo T, Yamamoto E, Kai M, Sasaki Y, Tokino T, Nakase H, Suzuki H. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling. Haematologica 2019;104:155-65. [PMID: 30171029 DOI: 10.3324/haematol.2018.191262] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
16 Harding T, Swanson J, Van Ness B. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. Oncotarget 2018;9:21930-42. [PMID: 29774113 DOI: 10.18632/oncotarget.25128] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]